We are i&i Prague, a bio-innovation center located right in the heart of Europe. Our objective is to identify the potential of new inventions in Drug Discovery, Diagnostics, MedTech and other Life Science fields. We do this by scouting for innovative projects and investing in the most promising ones. Then we will help with product development and, ultimately, market entry.
We can help you with
Our role
Mar 11 2024
This fall Prague will be the stage for a showcase of cutting-edge biotechnologies featuring prominent figures such as Christian A. Stein, Petr Jansa, and other leading experts.
The capital city of the Czech Republic is set to host the second Prague.bio Conference on September 24th 2024. The event unites top minds in biotechnology, representatives from major investment funds, technology transfer law specialists and other professionals from the biotech and medtech sectors. For ticket purchases, the project registration form and the latest news visit: www.conference.prague.bio.
Jan 30, 2024
CasInvent Pharma raises € 1.6 million from i&i Prague and Other Investors to Support the Development of CK1 Inhibitors for Treatment-Resistant Solid and Hematological Tumours
CasInvent Pharma, a university spin-off focused on developing anti-cancer compounds, has successfully closed the Pre-Series A funding round, raising a total of € 1.6 million from both existing and new investors. Founded in 2020 as a spin-off from Masaryk University in Brno and with the support of i&i Prague, CasInvent Pharma specializes in the development of highly selective inhibitors targeting the casein kinase 1 enzyme family....
Nov 30, 2023
IOCB Tech Group Successfully Represents the Czech Republic at the Prestigious Biotech Conference BIO-Europe 2023
Over 5,000 participants from more than 50 countries and a total of over 30,000 official meetings – that was the outcome of this year's edition of the international BIO-Europe conference in Munich. The Czech Republic was represented by the companies IOCB Tech, i&i Prague, and i&i Biotech Fund (i&i Bio)...
Feb 7, 2023
New startup in our portfolio: Sophomer's technology will make immunoassays faster, easier and cheaper
The academic startup Sophomer today announced the signing of a licensing agreement to commercialize a technology that can replace the traditionally used bovine serum albumin (BSA) in immunoassays. The newly licensed technology has been developed in collaboration between the Institute of Macromolecular Chemistry of the CAS (IMC), Elisa Development and the bio-innovation center i&i Prague. ...
Highlights
i&i Prague in numbers
15
We have created or otherwise supported 15 spin-off companies from 5 countries.
9
We have an equity stake in 9 spin-offs. We have already announced 3 exits.
1.8
Overall, the spin-offs in our portfolio have raised more than CZK 1.8 billion from other investors.
15
We helped sell 15 licenses to universities and other academic institutions.
